The estimated Net Worth of Venture Opportunity Fund Ii... is at least 30.5 百万$ dollars as of 12 December 2022. Venture Ii owns over 934,581 units of Dyne Therapeutics stock worth over 30,467,341$ and over the last 2 years Venture sold DYN stock worth over 0$.
Venture has made over 1 trades of the Dyne Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Venture bought 934,581 units of DYN stock worth 10,000,017$ on 12 December 2022.
The largest trade Venture's ever made was buying 934,581 units of Dyne Therapeutics stock on 12 December 2022 worth over 10,000,017$. On average, Venture trades about 934,581 units every 0 days since 2022. As of 12 December 2022 Venture still owns at least 934,581 units of Dyne Therapeutics stock.
You can see the complete history of Venture Ii stock trades at the bottom of the page.
Over the last 4 years, insiders at Dyne Therapeutics have traded over 197,573,300$ worth of Dyne Therapeutics stock and bought 5,790,447 units worth 92,382,301$ . The most active insiders traders include Capital Management, L.P.Kol...、Jason P Rhodes、Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of 3,566,016$. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth 68,914$.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: